{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:31:20Z","timestamp":1788618680850,"version":"build-2803163510"},"reference-count":29,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of iGlarLixi compared with iGlar in Chinese adults with type 2 diabetes advancing therapy from basal insulin\u2009\u00b1\u2009oral antihyperglycaemic drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>LixiLan\u2010L\u2010CN (NCT03798080) was a 30\u2010week randomized, active\u2010controlled, open\u2010label, parallel\u2010group, multicentre study. Participants were randomized 1:1 to iGlarLixi or iGlar. The primary objective was to show the superiority of iGlarLixi over iGlar in glycated haemoglobin (HbA1c) change from baseline to Week 30.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 426 participants were randomized to iGlarLixi (n\u00a0=\u00a0212) or iGlar (n\u00a0=\u00a0214). Mean age was 58\u2009years, 67% had a body mass index \u226524\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , corresponding to overweight\/obesity, and the mean diabetes duration was 12.3\u2009years. From mean baseline HbA1c of 8.1% in both groups, greater decreases were seen with iGlarLixi versus iGlar [least squares mean difference: \u22120.7 (95% confidence interval: \u22120.9, \u22120.6)%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.0001] to final HbA1c of 6.7% and 7.4%, respectively. HbA1c &lt;7.0% achievement was greater with iGlarLixi (63.3%) versus iGlar (29.9%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.0001). Mean body weight decreased with iGlarLixi and increased with iGlar [least squares mean difference: \u22120.9 (95% confidence interval: \u22121.4, \u22120.5)\u00a0kg;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a0.0001]. Hypoglycaemia incidence was similar between groups. Few gastrointestinal adverse events occurred (rated mild\/moderate) with a slightly higher incidence with iGlarLixi than iGlar.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>iGlarLixi provided better glycaemic control and facilitated more participants to reach glycaemic targets alongside beneficial effects on body weight, no additional risk of hypoglycaemia, and few gastrointestinal AEs, supporting iGlarLixi use as an efficacious and well tolerated therapy option in Chinese people with long\u2010standing T2D advancing therapy from basal insulin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.14803","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T06:50:37Z","timestamp":1656399037000},"page":"2182-2191","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Improved glycaemic control and weight benefit with\n                    <scp>iGlarLixi<\/scp>\n                    versus insulin glargine 100\u2009U\/\n                    <scp>mL<\/scp>\n                    in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the\n                    <scp>LixiLan\u2010L\u2010CN<\/scp>\n                    randomized controlled trial"],"prefix":"10.1111","volume":"24","author":[{"given":"Xiaoyong","family":"Yuan","sequence":"first","affiliation":[{"name":"Peking University First Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Guo","sequence":"additional","affiliation":[{"name":"Peking University First Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University First Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Dong","sequence":"additional","affiliation":[{"name":"Jinan Central Hospital  Jinan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibing","family":"Lu","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Nanjing Medical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuyan","family":"Pang","sequence":"additional","affiliation":[{"name":"Huaihe Hospital of Henan University  Kaifeng China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghong","family":"Gu","sequence":"additional","affiliation":[{"name":"Sanofi  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Niemoeller","sequence":"additional","affiliation":[{"name":"Sanofi  Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ping","sequence":"additional","affiliation":[{"name":"Sanofi  Bridgewater NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaowei","family":"Nian","sequence":"additional","affiliation":[{"name":"Sanofi  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Souhami","sequence":"additional","affiliation":[{"name":"Sanofi  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"LixiLan\u2010L\u2010CN investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,7,25]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"International Diabetes Federation.IDF Diabetes Atlas \u2013 Tenth Edition.2021;https:\/\/diabetesatlas.org\/. Accessed December 15 2021."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12886"},{"issue":"4","key":"e_1_2_10_4_1","first-page":"315","article-title":"Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)","volume":"13","author":"Chinese Diabetes Society","year":"2020","journal-title":"Chin J Diabetes Mellitus"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0917"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-2452"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14036"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1495"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14005"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1541790"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1235"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3062"},{"issue":"2","key":"e_1_2_10_13_1","article-title":"Characteristics of the pathophysiology of type 2 diabetes in Asians","volume":"2","author":"Cho YM","year":"2017","journal-title":"Ann Laparosc Endosc Surg"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.13046"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13936"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14722"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S104752"},{"key":"e_1_2_10_18_1","unstructured":"AgencyEM.Guidance on the management of clinical trials during the COVID\u201019 (coronavirus) pandemic.2021;https:\/\/ec.europa.eu\/health\/system\/files\/2021-02\/guidanceclinicaltrials_covid19_en_0.pdf. Accessed January 28 2022."},{"key":"e_1_2_10_19_1","unstructured":"Food and Drug Administration.Conduct of clinical trials of medical products during the COVID\u201019 public health emergency: Guidance for instudry investigators and institutional review boards.2021;https:\/\/www.fda.gov\/media\/136238\/download. Accessed September 23 2021 2021."},{"key":"e_1_2_10_20_1","unstructured":"Evaluation CFD.Drug Clinical Trial Management during the COVID\u201019 Outbreak \u2013 Guiding Principles.2020."},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S006"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3158"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2017.11.025"},{"key":"e_1_2_10_24_1","unstructured":"Agency EM.Suliqua public assessment report.2016;https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/suliqua-epar-public-assessment-report_en.pdf. Accessed March 10 2022."},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13607"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108848"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0990"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12618"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14522"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908292"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14803","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14803","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14803","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:40:59Z","timestamp":1761885659000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,25]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1111\/dom.14803"],"URL":"https:\/\/doi.org\/10.1111\/dom.14803","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,25]]},"assertion":[{"value":"2022-03-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}